VIDEO: Pegloticase, methotrexate treats uncontrolled gout without compromising kidney
Click Here to Manage Email Alerts
ORLANDO — In this video from ASN Kidney Week, Abdul A. Abdellatif, MD, discusses the efficacy of pegloticase treatment in conjunction with methotrexate for patients with uncontrolled gout.
Patients with uncontrolled gout were randomized 2:1 to either Krystexxa (pegloticase, Horizon Therapeutics) through a biweekly 8 mg infusion and a weekly blinded oral dose of methotrexate at 15 mg per week or placebo following a 2-week tolerance test to methotrexate and a 4-week blinded run-in of methotrexate and placebo. One-third of the patients in the study had moderate chronic kidney disease.
“Now, we know when the patients are treated with this medication, they have the ability to produce antibodies that may affect the efficacy of the drug and it creates the response too late,” Abdellatif told Healio. “However, what we showed [is] when you give Krystexxa in a combination with methotrexate, you not only improve the response rate, but you also significantly decrease the reaction rate in these patients.”
The eGFR of patients in the treatment group did not decrease after treatment; therefore, pegloticase used with methotrexate does not negatively impact the renal function of patients with uncontrolled gout, Abdellatif said.
“The label for Krystexxa has been updated by the FDA to include methotrexate as a condonement in immunomodulating therapy to improve the efficacy and safety in our patients. We’ve also shown that using methotrexate in patients, even with moderate kidney disease, was safe,” Abdellatif said.
Collapse
Abdellatif AA, et al. SA-PO898. Presented at: ASN Kidney Week; Nov. 3-6, 2022; Orlando (hybrid meeting).
Read more about
Click Here to Manage Email Alerts